Inhibrx Biosciences vs Scholar Rock
INBX and SRRK side by side, both in drugs. Figures are trailing twelve months unless noted, from SEC filings and end-of-day prices.
How INBX and SRRK compare
Scholar Rock is the larger company, worth 4.3 times as much as Inhibrx Biosciences ($5.3B against $1.2B).
Scholar Rock scores higher on the StockData Score (2 against 1 for Inhibrx Biosciences), which adds up 30 checks on valuation, growth, past performance, financial health and dividends.
Key numbers
A dot marks the better figure where higher or lower is clearly better.
| Metric | INBX | SRRK |
|---|---|---|
| Size and price | ||
| Market cap | $1.2B | $5.3B |
| Share price | $83.30 | $43.20 |
| Change, 1 year | 13.6% | 40.2% |
| Change, 5 years | 92.3% | 46.3% |
| Beta (5Y) | 1.70 | 1.50 |
| Employees | 110 | 289 |
| StockData Score | ||
| Total score | 1 | 2 (better) |
| Valuation score | 0 | 0 |
| Growth score | 0 | 0 |
| Performance score | 0 | 0 |
| Health score | 1 | 2 (better) |
| Dividend score | 0 | 0 |
| Valuation | ||
| P/S | – | 9231× |
| P/B | – | 31.2× |
| FCF yield | −10.8% | −5.9% (better) |
| Growth | ||
| Revenue growth, 5Y average | −36.8% | – |
| Profitability | ||
| Operating margin | – | −71732% |
| Net margin | – | −72563% |
| FCF margin | – | −54371% |
| Return on equity | – | −200% |
| Financial health | ||
| Debt / equity | – | 1.16 |
| Interest coverage | −5.9× (better) | −29.2× |
| Current ratio | 7.58 (better) | 5.41 |
| Altman Z-score | −0.76 | 4.22 (better) |
| Piotroski F-score | 1 | 1 |
| Dividends and buybacks | ||
| Buyback yield | – | −3.1% |
| Shareholder yield | 0.00% (better) | −3.1% |
| Ownership | ||
| Held by institutions | 97.4% | 114% |
| Held by insiders | 35.4% | 28.9% |
| Insider net buying, 12 months | $6.1M (better) | −$7.4M |
| Superinvestors holding | 1 | – |
| Short interest, % of float | 35.7% | 27.1% |
Go deeper
- INBX stock overview
- INBX income statement
- INBX valuation and score
- SRRK stock overview
- SRRK income statement
- SRRK valuation and score
For information only, not investment advice. Check the source filings before relying on any figure.